The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | The development of anti-fibrotic agents for treating myelofibrosis
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, discusses the potential use of anti-fibrotic agents for treating myelofibrosis (MF). Fibrosis is a critical player in the pathogenesis of the disease, and several agents are being developed in an attempt to normalize the morphology of the bone marrow. There is also a need to introduce a method that will allow for the use of fibrosis as an endpoint in clinical trials testing these agents. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Novartis, CTI Pharma, Incyte, Pfizer, Acceleron Pharma, Pharmaessentia.
